Cookies Policy

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

I accept this policy

Find out more here

Etodolac (Lodine®): Profile of an established selective COX-2 inhibitor

No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
The full text of this article is not currently available.

Brill’s MyBook program is exclusively available on BrillOnline Books and Journals. Students and scholars affiliated with an institution that has purchased a Brill E-Book on the BrillOnline platform automatically have access to the MyBook option for the title(s) acquired by the Library. Brill MyBook is a print-on-demand paperback copy which is sold at a favorably uniform low price.

Access this article

+ Tax (if applicable)
Add to Favorites
You must be logged in to use this functionality

image of Inflammopharmacology

Etodolac was developed in a search for a novel NSAID with an improved efficacy/side effect profile and was launched in the UK in 1985 for the acute and chronic treatment of arthritic conditions. The improved safety profile of etodolac when compared with other NSAIDs posed an anomaly for which there was no explanation at that time. However, the advent of the COX-2 theory served as a possible rationale for etodolac's improved safety profile, since etodolac has consistently shown selective COX-2 inhibition and COX-1 sparing effects across a wide range of assays. Since first discovery, etodolac has demonstrated a proven track record in a large number of clinical trials in patients with OA and RA extending to 7 years duration and over 14 years of clinical use.

Affiliations: 1: Shire Pharmaceuticals Limited, Andover, Hampshire, UK


Full text loading...


Data & Media loading...

Article metrics loading...



Can't access your account?
  • Tools

  • Add to Favorites
  • Printable version
  • Email this page
  • Subscribe to ToC alert
  • Get permissions
  • Recommend to your library

    You must fill out fields marked with: *

    Librarian details
    Your details
    Why are you recommending this title?
    Select reason:
    Inflammopharmacology — Recommend this title to your library
  • Export citations
  • Key

  • Full access
  • Open Access
  • Partial/No accessInformation